FV Leiden mutation and risk of recurrent venous thromboembolism in Serbian population

J Thromb Thrombolysis. 2008 Jun;25(3):284-7. doi: 10.1007/s11239-007-0059-z. Epub 2007 Jun 5.

Abstract

The absolute rate of recurrence of venous thromboembolism (VTE) is approximately 5% per year. There is a lower rate of recurrence in provoked VTE, and higher in idiopathic one. So far, there is no consensus whether hereditary thrombophilia should be considered as a persistent risk factor, and whether it requires long-term anticoagulant therapy. The aim of our study was to estimate the risk of recurrent VTE in patients carrying FV Leiden mutation in Serbian population. In retrospective study (1994-2006), we have evaluated the risk of recurrent VTE in 56 patients who are carriers of FV Leiden mutation, in comparison to group consisting of 56 patients non-carriers of FV Leiden mutation. Patients with FII G20210A and MTHFR C677T mutations, antiphospholipid antibodies, antithrombin III, protein C or protein S deficiency, malignancies and diabetes were excluded from the study. Recurrent VTE occurred in 44.6% of the patients, carriers of the FV Leiden mutations, vs. 26.7% in non-carriers group (P<0.05). The incidence rate was 3.7 and 2.2% per year, respectively. The estimated relative risk of recurrence for FV Leiden carriers was 1.67 (95% CI 0.99-2.81, P=0.049). The 60% of patients with mutation and only 13% without mutation develop rethrombosis during first year after discontinuance of therapy (P<0.01). In our study patients with symptomatic VTE who are carriers of the FV Leiden gene mutations have a higher risk of recurrent VTE than non-carriers. Our data suggest the importance of the FV Leiden mutation detection and the estimation of the clinical condition for successful secondary prophylaxis of VTE.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Anticoagulants / therapeutic use
  • Child
  • Child, Preschool
  • Factor V / genetics*
  • Female
  • Genetic Predisposition to Disease
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Recurrence
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Thrombophilia / complications
  • Thrombophilia / drug therapy
  • Thrombophilia / ethnology*
  • Thrombophilia / genetics*
  • Time Factors
  • Venous Thromboembolism / drug therapy
  • Venous Thromboembolism / ethnology*
  • Venous Thromboembolism / genetics*
  • Yugoslavia / epidemiology

Substances

  • Anticoagulants
  • factor V Leiden
  • Factor V